- Home
- CGON vs JBLU Comparison
CGON vs JBLU Comparison
Compare CGON & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- JBLU
- Stock Information
- Founded
- CGON 2010
- JBLU 1998
- Country
- CGON United States
- JBLU United States
- Employees
- CGON N/A
- JBLU N/A
- Industry
- CGON
- JBLU Air Freight/Delivery Services
- Sector
- CGON
- JBLU Consumer Discretionary
- Exchange
- CGON NYSE
- JBLU Nasdaq
- Market Cap
- CGON 2.1B
- JBLU 1.9B
- IPO Year
- CGON 2024
- JBLU N/A
- Fundamental
- Price
- CGON $26.90
- JBLU $4.45
- Analyst Decision
- CGON Strong Buy
- JBLU Sell
- Analyst Count
- CGON 10
- JBLU 11
- Target Price
- CGON $64.44
- JBLU $4.97
- AVG Volume (30 Days)
- CGON 864.2K
- JBLU 20.2M
- Earning Date
- CGON 08-07-2025
- JBLU 07-29-2025
- Dividend Yield
- CGON N/A
- JBLU N/A
- EPS Growth
- CGON N/A
- JBLU N/A
- EPS
- CGON N/A
- JBLU N/A
- Revenue
- CGON $662,000.00
- JBLU $9,210,000,000.00
- Revenue This Year
- CGON N/A
- JBLU N/A
- Revenue Next Year
- CGON $25,206.93
- JBLU $7.75
- P/E Ratio
- CGON N/A
- JBLU N/A
- Revenue Growth
- CGON 224.51
- JBLU N/A
- 52 Week Low
- CGON $14.80
- JBLU $3.34
- 52 Week High
- CGON $40.47
- JBLU $8.31
- Technical
- Relative Strength Index (RSI)
- CGON 59.29
- JBLU 48.31
- Support Level
- CGON $25.51
- JBLU $4.11
- Resistance Level
- CGON $27.28
- JBLU $4.39
- Average True Range (ATR)
- CGON 1.01
- JBLU 0.21
- MACD
- CGON 0.02
- JBLU 0.02
- Stochastic Oscillator
- CGON 89.23
- JBLU 74.70
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.